GlaxoSmithKline plc, Novartis AG, and Hikma Pharmaceuticals PLC are dominating the Europe Cold Sore Treatment market in 2021

Europe Cold Sore Treatment Market is expected to grow with the CAGR of 5.9 % in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-cold-sore-treatment-market

Europe Cold Sore Treatment market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favorable market scenario.

The major players dealing in Europe Cold Sore Treatment market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

• In December 2020, GlaxoSmithKline plc and Sanofi Inc had declared the delay in the adjuvant recombinant protein based COVID-19 vaccine programme to enhance immune response in the elderly population. This initiative by both the companies would result in delay of the cold sore treatment products, less revenue and less growth in the market.

GlaxoSmithKline plc is dominating player in Europe Cold Sore Treatment market. The other key players existing in the market includes Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc. (A Subsidiary of Zydus Cadila), Cipla Inc., AiCuris GmbH & Co. KG, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Aurobindo Pharma U.S.A. (A Subsidiary of Aurobindo Pharma), WOCKHARDT, Novartis AG, Hikma Pharmaceuticals PLC, Hetero Healthcare Limited, Apotex Inc., HRA Pharma among others.

GlaxoSmithKline plc

GlaxoSmithKline plc headquartered in Brentford, U.K. The company is focused on delivery of strategic properties which aims to improve growth, reduce risk, and improve long term financial performance. The company deals in multiple products such as pharmaceuticals, vaccines and consumer healthcare products. out of which consumer healthcare product is the market focused product portfolio.

• In December 2020, GlaxoSmithKline plc and Sanofi Inc had declared the delay in the adjuvant recombinant protein based COVID-19 vaccine programme to enhance immune response in the elderly population. This initiative by both the companies would result in delay of the cold sore treatment products, less revenue and less growth in the market.

The company has global presence in North America, Europe, Asia Pacific, Middle East & Africa and South America. The company has many subsidiaries such as GlaxoSmithKline Pharmaceuticals Ltd (Mumbai), Tesaro (Waltham, Massachusetts, United States), GlaxoSmithKline Pakistan (Karachi, Pakistan), Stiefel Laboratories (North Carolina, United States), Allen & Hanburys (Ware, United Kingdom), among others.

Novartis AG

Novartis AG was founded in 1996 and is headquartered in Basel, Switzerland. The company focuses on innovating for challenging healthcare solutions. The company has business segments such as Innovative Medicines, Sandoz and Alcon among which Innovative Medicines is the business focused segment. The company has multiple business categories such as Innovative Medicines, Sandoz and Alcon out of which Innovative Medicines are the market focused category.  

• In April 2020, Novartis AG had planned to initiate the clinical study of Jakavi in severe COVID-19 patients and to setup the International Compassionate Use Program. The initiative by the company would result in less distribution of Famvir among the consumers, less revenue would be incurred and negative growth in market would occur.

The company has global presence in the Americas, Asia Pacific, Europe, Middle East and Africa. The company has many subsidiaries such as Novartis Argentina S.A., Buenos Aires(Argentins), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde(Belgium), Novartis Securities Investment Ltd., Hamilton(Hamilton), Novartis Biociências S.A., São Paulo(Brazil), Sandoz (China) Pharmaceutical (hina)"among others.

            Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC headquartered in London, U.K. was founded in year 1978. The company is leading supplier of branded generics and in-licensed products. The company offers wide range of product in various categories such as Injectables, Generics, and Branded out of which generics and branded is market focused category.    

• In July 2019, Hikma Pharmaceuticals PLC has announced a 5 year agreement with Civica to supply and manufacture medication to the U.S. health systems. This will complete the shortage of medications in the U.S. hospitals. This will help the company to expand its business and make the product profile strong. The company has wide global presence in North America, Europe, Asia-Pacific and Middle East and Africa.

The company has global presence in the Europe, Middle East and Africa, Asia-Pacific, North America. The company has many subsidiaries such as Promopharm (Africa), Bedford Laboratories (London), Arab Pharmaceutical Manufacturing (Amman), Hikma Finance USA LLC (U.S.), Eurohealth (U.S.), Inc. among others.